CUSIP 98422T100COMXLOQ4 2025
Aggregate 13F value by quarter
Multi-quarter trend — upgrade to see history
UpgradeQ4 2025
37 funds hold this security · Q4 2025
| # | Fund | Shares | Value | Δ Shares | Activity |
|---|---|---|---|---|---|
| 1 | Gilead Sciences, Inc. | 9.11M | $5.83M | 0 | Held |
| 2 | Bain Capital Life Sciences Investors, LLC | 7.37M | $4.72M | +2.81M | Added |
| 3 | Frazier Life Sciences Management, L.P. | 5.92M | $3.79M | +5.92M | New |
| 4 | Point72 Asset Management, L.P. | 4.00M | $2.56M |
| +4.00M |
| New |
| 5 | Sio Capital Management, LLC | 2.13M | $1.37M | +2.13M | New |
| 6 | Stempoint Capital LP | 2.03M | $1.30M | +2.03M | New |
| 7 | Merck & Co., Inc. | 1.48M | $949.9K | 0 | Held |
| 8 | Vanguard Group Inc | 1.26M | $803.6K | 0 | Held |
| 9 | Empery Asset Management, LP | 1.18M | $757.4K | +1.18M | New Position |
| 10 | Ghisallo Capital Management LLC | 1.11M | $712.7K | +1.11M | New |
See every fund holding Xilio Therapeutics Inc, with full quarter-over-quarter share changes.
Unlock all holders